Progression of Benign Breast Tumors: A Review of Differential Expression of BRCA1
Abstract
Abstract Views: 121
Benign breast tumors, a group of heterogeneous disorders, have a high incidence in females which is the effect of multiple environmental and genetic factors. Some notable genetic factors include the involvement of the highly penetrant BRCA1 gene and its major interactions with other genetic activators. BRCA1’s interaction with certain proteins, such as 53BP-1 and ATM kinases, is initiated through the phosphorylation of their respective domains to create varied complexes with different functions. Consequently, BRCA1/BACH complex formation, in particular, helps in DNA repair processes. When this formation mutates, it can produce severe benign breast tumors. On the other hand, TP53 gene mutation also causes high damage to breast epithelia, irrespective of its interaction with BRCA1 function. BARD1 protein is also known to assist BRCA1 in maintaining its phenotype during the entire process of repair. These complex formations reveal the dual functioning of BRCA1 in relation to different proteinaceous entities as a tumor suppressor gene and a breast disease causing gene. Thus, this study focuses on BRCA1 mutation, its interaction with other genes, and its role in the DNA repair processes.
Downloads
References
Klann E, Williamson JM, Tagliamonte MS, et al. 2020. Microbiota composition in bilateral healthy breast tissue and breast tumors. Cancer Causes & Control, 31(11), pp.1027-1038
https://doi.org/10.1007/s10552-020-01338-5
Perou CM, Sørlie T, Eisen MB, et al. 2000. Molecular portraits of human breast tumours. Nature. 406(6797):747-52..
https://doi.org/10.1038/35021093
Singh VK and Sharma PK. 2020. Oxidative Stress and Lifestyle-based Changes in Breast Cancer Progression. Current Advances in Breast Cancer Research: A Molecular Approach, pp.208-235.
https://doi.org/10.2174/9789811451447120010011
Tahiri A, Leivonen S, Lüders T, et al. 2014. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 35 (1) 76-85
https://doi.org/10.1093/carcin/bgt333
Lyn, FM, Traynor D, Nguyen TNQ, et al. 2019. Discrimination of breast cancer from benign tumours using Raman spectroscopy. PLoS One, 14(2), p.e0212376.
https://doi.org/10.1371/journal.pone.0212376
Laakso M, Loman N, Borg A, Isola J. 2005. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Modern Pathology 18, 1321-1328
https://doi.org/10.1038/modpathol.3800456
Khan RT, Siddique A, Shahid N, et al. 2018. Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan. Breast Cancer, 25(3), pp.350-355.
https://doi.org/10.1007/s12282-018-0837-9
Miltenburg DM and Speights Jr VO. 2008. Benign breast disease. Obstetrics and gynecology clinics of North America, 35(2), pp.285-300.
https://doi.org/10.1016/j.ogc.2008.03.008
Sasaki J, Geletzke A, Kass RB, et al. 2018. Etiology and management of benign breast disease. In The Breast (pp. 79-92). Elsevier
https://doi.org/10.1016/B978-0-323-35955-9.00005-2
Onstad M, and Stuckey A. 2013. Benign Breast Disorders. Obstetrics and Gynecology Clinics of North America Volume 40, Issue 3, September 2013, Pages 459-473
https://doi.org/10.1016/j.ogc.2013.05.004
Biglia N, Bounous VE, D'Alonzo M. et al. 2020. Hormones, Breast Disorders, and Lactation. Female Reproductive Dysfunction, pp.433-460.
https://doi.org/10.1007/978-3-030-14782-2_22
Memon A, Parveen S, Sangrarasi AK. et al. 2007. Changing Pattern of Benign Breast Lumps in Young Females. World Journal of Medical Sciences 2 (1): 21-24, 2007
Figueroa JD, Gierach GL, Duggan MA, et al. 2021. Risk factors for breast cancer development by tumor characteristics among women with benign breast disease. Breast Cancer Research, 23(1), pp.1-12
https://doi.org/10.1186/s13058-021-01410-1
Allred DC and Mohsin SK. 2000. Biological features of premalignant disease in the human breast. Journal of mammary gland biology and neoplasia 5(4): 351-364
https://doi.org/10.1023/A:1009573710675
Jolly MK and Celià-Terrass, T. 2019. Dynamics of phenotypic heterogeneity associated with EMT and stemness during cancer progression. Journal of clinical medicine, 8(10), p.1542.
https://doi.org/10.3390/jcm8101542
Wood LD, Parsons DW, Jones S, et al. 2007. The genomic landscapes of human breast and colorectal cancers. Science, 318(5853), pp.1108-1113.
https://doi.org/10.1126/science.1145720
Loke BN, Nasir NDM, Thike AA, et al. 2018. Genetics and genomics of breast fibroadenomas. Journal of clinical pathology, 71(5), pp.381-387.
https://doi.org/10.1136/jclinpath-2017-204838
Johansson A, Christakou AE, Iftimi A, et al. 2021. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open, 4(6), pp.e2114716-e2114716.
https://doi.org/10.1001/jamanetworkopen.2021.14716
Khanzada TW, Samad A, Sushel C. 2009. Spectrum of benign breast diseases. Pak J Med Sci, 25(2), pp.265-268.
Li NA, Deng Y, Zhou L, Tian T, et al. 2019. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017. Journal of hematology & oncology, 12(1), pp.1-12.
https://doi.org/10.1186/s13045-019-0828-0
Salzman B, Fleegle S, et al. 2012. Common breast problems. American family physician 86(4)
Johansson A, Christakou AE, Iftimi A, et al. 2021. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open, 4(6), pp.e2114716-e2114716.
https://doi.org/10.1001/jamanetworkopen.2021.14716
Aslam HM, Saleem S, et al. 2013. Clinico-pathological profile of patients with breast diseases. Diagnostic pathology 8(1): 77
https://doi.org/10.1186/1746-1596-8-77
Wu LC, Wang ZW, Tsan JT, et al. 1996. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nature genetics, 14(4), pp.430-440.
https://doi.org/10.1038/ng1296-430
Abass S, Fatima W, Mahmood S. 2016. Homologous DNA repair: safeguarding genome territories from knives. Current Science, pp.1335-1339.
https://doi.org/10.18520/cs/v111/i8/1335-1339
Patel PS, Algouneh A, Hakem R. 2021. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene, 40(17), pp.3001-3014.
https://doi.org/10.1038/s41388-021-01744-2
Williams SA. 2011. Maintenance of Genomic Integrity through Regulation of the FA-BRCA Pathway. Yale University.
Shin DS, Chahwan C, Huffman JL, et al. 2004. Structure and function of the double-strand break repair machinery. DNA repair, 3(8-9), pp.863-873.
https://doi.org/10.1016/j.dnarep.2004.03.022
Tarsounas M, Sung P. 2020. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology, 21(5), pp.284-299.
https://doi.org/10.1038/s41580-020-0218-z
Xu X, Weaver Z, Linke SP, et al. 1999. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Molecular cell, 3(3), pp.389-395.
https://doi.org/10.1016/S1097-2765(00)80466-9
Wang H, Xiang D, Liu B, et al. 2019. Inadequate DNA damage repair promotes mammary transdifferentiation, leading to BRCA1 breast cancer. Cell, 178(1), pp.135-151.)
https://doi.org/10.1016/j.cell.2019.06.002
Morales JC, Xia Z, et al. 2003. Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability. Journal of Biological Chemistry 278(17): 14971-14977
https://doi.org/10.1074/jbc.M212484200
Wang B, Matsuoka S, et al. 2002. 53BP1, a mediator of the DNA damage checkpoint. Science 298(5597): 1435-1438
https://doi.org/10.1126/science.1076182
Alhmoud JF, Woolley JF, Al Moustafa AE et al. 2020. DNA damage/repair management in cancers. Cancers, 12(4), p.1050.
https://doi.org/10.3390/cancers12041050
Das B, Choudhury B, Kumar A, et al. 2021. Genome Instability and DNA Repair in Cancer. In DNA Repair. IntechOpen.
https://doi.org/10.5772/intechopen.95736
Zhang J, Powell SN. 2005. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Molecular Cancer Research 3(10): 531-539
https://doi.org/10.1158/1541-7786.MCR-05-0192
Zhou B, Elledge SJ. 2000. The DNA damage response: putting checkpoints in perspective, Nature 408, 433-439
https://doi.org/10.1038/35044005
Takaoka M, Miki Y. 2018. BRCA1 gene: function and deficiency. International journal of clinical oncology, 23(1), pp.36-44
https://doi.org/10.1007/s10147-017-1182-2
Wang B, Matsuoka S, Ballif BA, et al. 2007. Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response, Science, 316 (5828):1194-1198
https://doi.org/10.1126/science.1139476
Cortez D, Wang Y, Qin J, et al. 1999. Requirement of ATM-Dependent Phosphorylation of Brca1 in the DNA Damage Response to Double-Strand Breaks, Science.286 (5442) :1162-1166
https://doi.org/10.1126/science.286.5442.1162
Billing D, Horiguchi M, Wu-Baer F, et al. 2018. The BRCT domains of the BRCA1 and BARD1 tumor suppressors differentially regulate homology-directed repair and stalled fork protection. Molecular cell, 72(1), pp.127-139.
https://doi.org/10.1016/j.molcel.2018.08.016
Manié E, Vincent-Salomon A, Lehmann-Che J, et al. 2009. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer research, 69(2), pp.663-671.
https://doi.org/10.1158/0008-5472.CAN-08-1560
Tarsounas M, Sung P. 2020. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology, 21(5), pp.284-299
https://doi.org/10.1038/s41580-020-0218-z
Brzovic PS, Rajagopal P, Hoyt DW, et al. 2001. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nature structural biology, 8(10), pp.833-837.
https://doi.org/10.1038/nsb1001-833
Mikolaskova B, Jurcik M, Cipakova I, et al. 2018. Maintenance of genome stability: the unifying role of interconnections between the DNA damage response and RNA-processing pathways. Current genetics, 64(5), pp.971-983.
https://doi.org/10.1007/s00294-018-0819-7
Kleiman FE, Wu-Baer F, Fonseca D, et al. 2005. BRCA1/BARD1 inhibition of mRNA 3′ processing involves targeted degradation of RNA polymerase II. Genes & development, 19(10), pp.1227-1237.
https://doi.org/10.1101/gad.1309505
Aquila L, Atanassov BS. 2020. Regulation of histone ubiquitination in response to DNA double strand breaks. Cells, 9(7), p.1699
Copyright (c) 2021 Warda Fatima, Unzila Yasin
This work is licensed under a Creative Commons Attribution 4.0 International License.
